top of page
green grasses_edited.jpg

Cultivating Breakthroughs
   - Harnessing the Power of Academic Seeds
      in Cancer Therapy

A-SEEDS, an innovative biotech company sprouted from Shinshu University, is dedicated to pioneering advanced treatments for life-threatening cancers. Harnessing the potential of non-viral genetic engineering, our cutting-edge immune cell therapy opens up new horizons of hope for patients seeking effective and transformative solutions.

ホーム: ようこそ!

News/Press release


A-SEEDS Co., Ltd. Receives Award from the New Energy and Industrial Technology Development Organization (NEDO) for the Deep Tech Startup Support Project (DTSU)

A-SEEDS Co., Ltd. (located in Matsumoto, Nagano Prefecture; CEO: Shigeki Yagyu, hereinafter referred to as "the Company"), is delighted to announce our selection in the Practical Application and Commercialization Phase of the third round of the 2023 Deep Tech Startup Support Project (DTSU), administered by the National Research and Development Agency, New Energy and Industrial Technology Development Organization (NEDO). This award supports our continued efforts to advance the clinical application of CAR-T cell therapy, with the goal of offering this innovative treatment to cancer patients who currently have limited therapeutic options.


A-SEEDS Co., Ltd. Secured 440 M JPY in Seed Round Funding for Pioneering Global Trials of CAR-T Cell Therapy

A-SEEDS Co., Ltd. has achieved a significant milestone by raising 440 million yen in seed funding, contributed by Hachijuni Investment Co., Ltd. and Greencore Co., Ltd. This capital injection is pivotal in underpinning the preparatory phase for clinical trials in the United States, slated for initiation in 2024. The funds will enable technology transfers in CAR-T cell production and bolster our organizational structure and research and development capabilities. This crucial phase of funding is instrumental as we advance toward an ambitious capital mobilization to reinforce our clinical trial endeavors in the U.S.

Unleashing the Power of Non-Viral
Gene-Modified CAR-T Cell Therapy

At A-SEEDS, we are driven by a profound purpose:

"To redefine the landscape of cancer treatment and ignite a ray of hope for a brighter future".

Our unwavering commitment is to provide highly effective therapies that reach a multitude of individuals, transforming their lives in the battle against cancer.


Pioneering Limitless Potential

Deep within the core of our mission resides a dynamic team of distinguished medical professionals, researchers, and experts in non-clinical safety studies and clinical trial support.

Together, we share a resolute vision:

"To unleash the extraordinary power of non-viral gene-modified CAR-T cell therapy."

Transforming Vision into Life-Altering Treatment

We seamlessly unite each stage of development, embarking on an exceptional voyage that encompasses groundbreaking research, meticulous non-clinical trials, and swift clinical implementation.

Through our relentless pursuit of innovation, we endeavor to bring to fruition a therapy that redefines the realm of cancer treatment.

Enabling Swift Accessibility

Our ultimate goal is to accelerate the delivery of this pioneering therapy to a multitude of patients, leaving an indelible impact on their lives.

By bridging the gap between scientific discovery and patient care, we aim to empower individuals with timely access to life-changing treatments, fostering a society where hope triumphs over cancer.

ホーム: 概要
bottom of page